美国 · 股市与财经 · CNBC

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

来源：CNBC · 美国 1 小时前

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.

在 CNBC 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.cnbc.com)

推荐阅读

Achieve a new Buy at Stifel on potential of smoking cessation drug cytisinicline

E.E.O.C. Sues Harvard for Data on Diversity in Hiring Practices

Business Insider

15 US colleges now cost more than $100,000 a year. See the list, ranked by cost of attendance.

Open USD takes on Tether, Circle with a different stablecoin model that's 'building money'

The 'Gen Z stare' is telling us something important about today's economy

FedEx orders 2,000 electric trucks from Harbinger in $300M deal